SCHEMBL1886255

SCHEMBL1886255

Nc1nc(-c2cccc(NC(=O)CCC(=O)O)c2)c2cc(Cl)ccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 2/20 0.47
HSP90AB1 P08238 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
PARP1 P09874 2/20 0.43
GFER P55789 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
JAK3 P52333 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1874439 0.93 AURKA (0.47) MEN1KMT2AALDH1A1HSP90AB1L3MBTL1
SCHEMBL1887528 0.93 HSP90AB1 (0.48) ALDH1A1HSP90AB1L3MBTL1PARP1KDM4E
SCHEMBL1877364 0.90 AURKA (0.47) MEN1KMT2AHSP90AB1L3MBTL1AURKA
SCHEMBL1875749 0.90 HDAC1 (0.46) ALDH1A1HSP90AB1L3MBTL1PARP1KDM4E
SCHEMBL1876317 0.88 MAP4K4 (0.53) MEN1KMT2AALDH1A1HSP90AB1KDM4E
SCHEMBL1877738 0.85 HSP90AB1 (0.54) MEN1KMT2AALDH1A1HSP90AB1KDM4E
SCHEMBL1882463 0.83 NPC1 (0.54) MEN1KMT2AALDH1A1HSP90AB1GFER
SCHEMBL1877650 0.83 MEN1 (0.53) MEN1KMT2AHSP90AB1L3MBTL1KDM4E
SCHEMBL1874678 0.83 ADORA3 (0.49) ALDH1A1HSP90AB1KDM4EHPGDGAA
SCHEMBL1874112 0.82 HSP90AB1 (0.48) MEN1KMT2AHSP90AB1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US claimed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US claimed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN claimed
US-7947696-B2 heat shock proteins inhibition, regulation and/or modulation; tumour diseases, viral diseases, for immune suppression in transplants, inflammation-induced diseases, cystic fibrosis, diseases associated with angiogenesis, infectious diseases, autoimmune diseases, ischaemia, fibrogenetic diseases MERCK PATENT GMBH (DE) 2011-05-24 US disclosed
CN-101180278-B 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH 2011-05-04 CN disclosed
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators MERCK PATENT GMBH (DE) 2008-09-04 US disclosed
CN-101180278-A 2-amino-4-phenylquinazoline derivates and their use as HSP90 modulators MERCK PATENT GMBH (DE) 2008-05-14 CN disclosed
EP-1881965-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS Merck Patent GmbH (DE) 2008-01-30 EP disclosed
WO-2006122631-A1 2-AMINO-4-PHENYLQUINAZOLINE DERIVATES AND THEIR USE AS HSP90 MODULATORS MERCK PATENT GMBH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214586-A1 2-Amino-4-Phenylquinazoline Derivatives and the Use Thereof as Hsp90 Modulators HSP90AB2P, HSP90AB1, HSP90AA1 MEN1 4729/4885KMT2A 2946/4885ALDH1A1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.